The aim of this study is to evaluate the intra/perioperative fluid management and early postoperative outcomes of patients who underwent radical cystectomy with Enhanced Recovery After Surgery protocol, using goal-directed fluid therapy compared to conventional fluid therapy.
(UroToday.com) High dose chemotherapy/autologous stem cell transplantation represents a curative salvage treatment for patients with germ cell tumors but is rarely used for other solid tumors. Patients undergoing high dose chemotherapy/autologous stem cell transplantation for hematologic neoplasms require revaccination for their childhood immunizations. Whether this is necessary for patients with germ cell tumor patients is […]
Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU Medical Oncologist and Associate Professor of Medicine at Northwestern University in Chicago in the U.S. I’m so excited to have here with me today a good friend and colleague Dr. Rana McKay. Who’s an Associate Professor of Medicine and a GU Medical Oncologist […]
Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU Medical Oncologist and Associate Professor of Medicine at Northwestern University in Chicago. I’m so excited to talk today with a good friend and colleague Dr. Mary-Ellen Taplin, who is a Professor of Medicine at Harvard Medical School, as well as being a GU […]
(UroToday.com) In this session, Dr. Rana McKay discussed late-breaking abstract 5, results from the KEYNOTE-564 (KN-564) study of adjuvant pembrolizumab in resected clear-cell renal cell carcinoma (RCC).
(UroToday.com) In 2018, kidney cancer was responsible for 175,000 deaths worldwide. Nephrectomy is the standard of care treatment for locoregional RCC, however, there is no globally accepted standard adjuvant therapy supported by high levels of evidence. Studies of adjuvant immunotherapy with cytokines have yielded negative results and VEGF-targeted therapy has not shown a consistent benefit in […]
(UroToday.com) Following Micheal Morris’s presentation of the results of the phase III VISION trial of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer in the Plenary Session of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Mary-Ellen Taplin from the Dana Farber Cancer Institute provided a discussant overview of these data and helped […]
(UroToday.com) Dr. Franklin Huang focused his presentation on the role of genomic testing in metastatic prostate cancer and how it influences therapeutic decision-making for medical oncologists. He specifically focused on genomic testing for microsatellite instability, tumor mutational burden, and DNA damage repair deficiency and the role of immunotherapy and PARP inhibitors for these alterations.
(UroToday.com) Dr. Veda Giri began by providing the historical context of genetic testing in prostate cancer. Unlike germline genetic testing in breast and ovarian cancer (BRCA) and Lynch syndrome testing, prostate cancer genetic profiling began much later, around 2014. Current genomic tests for prostate cancer are summarized in the table provided below and cross-referenced with their […]
(UroToday.com) Oncology patients experience more severe disease outcomes from COVID-19 infection than the general population. BCG is a live bovine tuberculosis bacillus with immunotherapeutic effects in urothelial cancers, and it is also used as a vaccination against Mycobacterium tuberculosis in parts of the world. As BCG vaccination has been associated with broad protection against viral pathogens, BCG […]
